Perturbations in the Acrp30 system, as we have demonstrated in lung cancer patients, may result in the modulation of anti-proliferative and anti-inflammatory effects induced by Acrp30, which might offer novel therapeutic options for patients with NSCLC. This evidence concerns the gene ADIPOQ and lung carcinoma.